Skip to main content

Table 1 Baseline characteristics of patients in the cyclophosphamide (CYC) and mycophenolate mofetil (MMF) groups

From: Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study

Parameter* CYC (n = 25) MMF (n = 25)
Age at recruitment (years) 31.4 ± 6.4 28.4 ± 4.4
Age at diagnosis (years) 28.4 ± 6.1 24.1 ± 4.4
Duration of disease from diagnosis (years) 3 ± 2.9 4.3 ± 4
SLEDAI 7.2 ± 2.5 5.8 ± 3.4
Marital status
 Unmarried 6 (24%) 8 (32%)
 Completed family 13 (52%) 6 (24%)
Gestational history
 Median number of successful pregnancies 1 1
 Median number of abortions 0 0
Menstrual cycles at recruitment
 Regular 24 (96%) 24 (96%)
 Oligomenorrhoea 1 (4%) 1 (4%)
ANA positivity 25 (100%) 25 (100%)
dsDNA positivity 21 (84%) 23 (92%)
Hypocomplementaemia 17 (68%) 13 (52%)
Creatinine (mg/dl) 1.38 ± 0.92 0.93 ± 0.56
TSH (mIU/l) 3.37 ± 1.95 2.69 ± 2.24
Testosterone (nmol/l) 0.29 ± 0.35 0.47 ± 0.71
Prolactin (ng/ml) 18.26 ± 7.60 23.31 ± 21.02
Kidney biopsy class
 Class II 1 (5%) 1 (4.5%)
 Class III 2 (10%) 5 (23.7%)
 Class IV 12 (60%) 6 (27.3%)
 Class III + V 0 1 (4.5%)
 Class IV + V 5 (25%) 2 (9%)
 Class V 0 7 (32%)
  1. CYC cyclophosphamide, MMF mycophenolate mofetil, SLEDAI Systemic Lupus Erythematosus Disease Activity Index, ANA antinuclear antibodies, dsDNA anti-double-stranded deoxyribonucleic acid antibodies, TSH thyroid-stimulating hormone
  2. *Reported as mean ± SD or n (%)